Kyung Hee Medical Research Institute signs MOU with Progen and ODEN to develop obesity and diabetes treatments

Kyung Hee Medical Research Institute announced on the 22nd that it signed a tripartite business agreement (MOU) with Progen and Odien to develop treatments for obesity and diabetes.

Progen is a company developing obesity and diabetes treatments, and ODN is a digital medical device startup from the Kyunghee Digital Health Center.

According to this agreement, each organization will: △Establish and carry out clinical evaluation strategies to develop next-generation obesity and diabetes treatments △Develop clinical protocols for evaluating efficacy in patients with severe obesity △Collect and maintain review of efficacy and safety data on patients with severe obesity. △Digital treatment We decided to collaborate in presenting a platform for the treatment of chronic diseases for patients with severe obesity through the use of devices.

The Director of Kyung Hee Medical Research Institute, Kyung-Sik Yoon, said, “We hope that this MOU signing will find the best approach for treating obesity and diabetes patients,” saying, ” Based on Kyung Hee Medical Research Institute’s diverse research experience and big data infrastructure, we will provide the best results.” “We will spare no support,” he said.

Kim Jong-gyun, CEO of Progen, said, “PG-102, a treatment for obesity and diabetes, is an innovative (first-in-class) dual-agonist drug that simultaneously targets GLP receptors -1 and GLP-2, and is being developed as a monthly injection and weekly oral administration “We received approval for a phase 2 clinical trial focusing on obese and diabetic patients in July,” he said.

Lee Sang-yeol, CEO of ODN (Professor of Endocrinology, Kyung Hee University Hospital), said, “The goal is to improve the health of obese and diabetic patients through personalized digital treatment tools based on artificial intelligence and provide patients with a better life. through scientific methods and the development of innovative technology “Our goal is,” he said, “In particular, we expect to be able to develop a new level of digital medicine through the collaboration this is by Progen.”